Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorBeijing Tongren Hospital
About this trial
The patients diagnosed with relapsed/refractory or advanced NK/T-cell Lymphoma (r/r NKTCL) were selected as the research objects. To explore effective and safe treatment for advanced or r/r NKTCL, the combination of PI3K-δ inhibitor Linperlisib with PD-1 blockade Camrelizumab and anti-metabolic agent Pegaspargase was applied for the treatment.
Eligibility criteria
Qualifiers
Histopathology and immunohistochemistry confirmed diagnosis of ENKTL according to WHO 2016 criteria.
refractory or relapsed after initial remission, or Ann-Arbor stage III-IV de novo patients
PET/CT or CT/MRI with at least one objectively evaluable lesion.
Expected to survive more than 3 months.
Disqualifiers
Patients with CNS involvement, or with other neoplasm;
Patients has received PI3K inhibitor treatment before enrollment
Poor performance status, ECOG≥2;
Patients in lactation or pregnancy；
Trial design
Treatments tested in this trial
- Linperlisib
- Camrelizumab
- Pegaspargase
- Dexamethasone
Treatment groups
43 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov